Since Pfizer and our collaboration partner, BioNTech, begun our mission to develop a COVID-19 vaccine, safety has been our guiding principle every step of the way. At the same time, given the urgency of the global pandemic, we continue to move at record-breaking speed. We recently started the phase […]
Click here to view original web page at www.pfizer.com
Expediting the development of a potential #COVID19 vaccine is important, with safety at the forefront.
— Pfizer Inc. (@pfizer) July 27, 2020
Read how we’re collaborating and marshaling our expertise as we seek to develop a safe, effective and accessible #vaccine:
UPDATE: $PFE $BNTX mRNA-based #vaccine candidate against SARS-CoV-2 (BNT162b2) is moving into Phase 2/3 clinical development and enrollment.
— Pfizer Inc. (@pfizer) July 27, 2020
➡️ Read the release: https://t.co/9PmDiChTCs #COVID19 @BioNTech_Group pic.twitter.com/LQiOVlzlP3